On July 1, the Rheumatology Research Foundation awarded grants to a wide range of rheumatology trainees and professionals. The recipients will receive funding for essential education and training, as well as innovative research projects. Their applications were closely examined by experts in different areas of the field to ensure awards went to the most promising…
The ACR and the ARHP have a long, rich history of collaboration, spanning close to 25 years together. Our predecessors saw the value of an interprofessional team and having an organization that brings together a vast number of constituencies. The result was these two organizations coming together in 1994 when the ARHP became a division…
Within 10 years of diagnosis, 23–45% of patients with rheumatic and musculoskeletal disease may become unemployed due to disease-related disability. Intervention programs may be necessary to prevent this work loss. New research examined if a vocational rehabilitation program delivered by occupational and physical therapists can benefit this patient population…
Many patients with rheumatoid arthritis (RA) report pain despite excellent control of inflammation with immunotherapies. Variable degrees of coexisting fibromyalgia (FM) may explain this disparity. RA patients who have the highest 2011 ACR FM survey criteria scores appear to share neurobiologic features consistently observed in FM patients. This study is the first to provide neuroimaging evidence that RA is a mixed pain state, with many patients’ symptoms being related to the central nervous system rather than to classic inflammatory mechanisms…
(Reuters Health)—Obese people with knee osteoarthritis (OA) may find greater symptom relief when they lose larger amounts of weight, a recent study suggests. Researchers examined data on 240 obese adults with pain from knee OA who were participating in an 18-month experiment to see how diet alone or diet plus exercise affected their health. Participants…
New research examines the adherence rates for system-level performance measures in Canada. Using data from the Canadian Early Arthritis Cohort that spanned eight years, researchers determined the percentage of RA patients seen in yearly follow-up with the number of gaps between visits, the percentage of RA patients treated with a disease-modifying anti-rheumatic drug and number days from diagnosis to the initiation of treatment. The results: High adherence to system-level performance measures was found in this early RA cohort, with small declines in performance with the increasing length overtime…
Few opportunities exist for rheumatologists in community-based practice who, in addition to taking care of patients, want to test their own observations through research. Limited funding, time constraints and competition from larger academic medical centers are some of the barriers hindering clinical research in this setting. The Rheumatology Research Foundation is addressing this issue with…
Gut microbiota may provide insight into important environmental triggers for autoimmune diseases. New research in mice indicates that intestinal dysbiosis triggers a mucosal immune response that stimulates T and B cells, which are critical to the development of inflammatory arthritis…
New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…
NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial. Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard…